Impact of Recurrence Score on Adjuvant Treatment Decisions in Breast Cancer Patients
NCT ID: NCT03961880
Last Updated: 2025-09-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
270 participants
OBSERVATIONAL
2019-03-01
2025-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Treatment Decision Impact of OncotypeDX™ in HR+, N- Breast Cancer Patients
NCT01446185
Adjuvant Treatment in Premenopausal Breast Cancer
NCT06807749
Partial Breast Re-irradiation in Women in Women with Locally Recurrent Breast Cancer Previously Treated with Conservative Surgery and Whole Breast Irradiation
NCT05772390
Recurrence Risk Evaluation by 21-gene Detection
NCT03841266
Prognostic and Predictive Factors for Small Breast Tumors
NCT03390608
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* histologically proven unilateral primary non-metastatic invasive breast cancer
* ER-/ or PR- positive and HER2-negative
* N0-N1 (0-3 involved lymph-nodes). The nodal status may be evaluated clinically.
* surgery or planed surgery at the Department of women's health, Tuebingen
* written informed consent into IRMA
Exclusion Criteria
* HER2-positive
* \> 3 involved lymph-nodes
* bilateral breast cancer
* preexisting cancer disease within the last 10 years
* primary systemic therapy
* locally advanced, inoperable or metastatic breast cancer
* pregnant or lactating patients
* inadequate general condition (not fit for chemotherapy)
18 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital Tuebingen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department for Women's Health
Tübingen, Baden-Wurttemberg, Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRMA
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.